Source: International Congress 2015 – Treatment of IPF
Disease area: Interstitial lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
Ganesh Raghu (Seattle, United States of America), Ganesh Raghu, Bruno Crestani, Zelie Bailes, Rozsa Schlenker-Herceg, Ulrich Costabel. Effect of anti-acid medication on reduction in FVC decline with nintedanib. Eur Respir J 2015; 46: Suppl. 59, 4502

Member's Comments

No comment yet.

Related content which might interest you: Effect of baseline corticosteroid medication on reduction in FVC decline with nintedanib Source: International Congress 2015 – Treatment of IPF Year: 2015 Effect of baseline FVC on lung function decline with nintedanib in patients with IPF Source: International Congress 2015 – Treatment of IPF Year: 2015 Effect of baseline statin use on benefit of nintedanib Source: International Congress 2016 – IPF treatment II Year: 2016 Effect of baseline composite physiologic index on benefit of nintedanib in IPF Source: International Congress 2016 – IPF treatment I Year: 2016 Real World experiences: Pirfenidone is well tolerated and reduces decline in FVC and TLCO at 9 months in IPF Source: Annual Congress 2013 –Diffuse pulmonary fibrosis Year: 2013 Efficacy and safety of nintedanib in advanced idiopathic pulmonary fibrosis Source: International Congress 2016 – IPF: from pathogenesis to treatment II Year: 2016 Relationship between nintedanib exposure and adverse events in patients with idiopathic pulmonary fibrosis Source: International Congress 2016 – IPF treatment II Year: 2016 Long-term treatment with nintedanib in patients with IPF: An update from INPULSIS®-ON Source: International Congress 2016 – IPF treatment II Year: 2016 Long-term safety of combination therapy with nintedanib and pirfenidone in Japanese patients with IPF Source: International Congress 2016 – IPF: from pathogenesis to treatment II Year: 2016 Clinical experience with pirfenidone for the treatment of idiopathic pulmonary fibrosis Source: Annual Congress 2013 –Diffuse parenchymal lung disease III Year: 2013 Effect of baseline FVC on decline in lung function with nintedanib: Results from the INPULSIS™ trials Source: International Congress 2014 – Clinical trials in IPF Year: 2014 Differences in FVC decline by extent of emphysema in patients with combined pulmonary fibrosis and emphysema (CPFE) syndrome Source: International Congress 2015 – New frontiers in the management of interstitial and orphan lung diseases Year: 2015 Efficacy of pirfenidone in idiopathic pulmonary fibrosis: A single center experience Source: International Congress 2016 – IPF: from pathogenesis to treatment II Year: 2016 Clinical experience with nintedanib for the treatment of IPF in 80 cases Source: International Congress 2016 – IPF: from pathogenesis to treatment II Year: 2016 No effect of baseline diffusing capacity of lung for carbon monoxide on benefit of nintedanib Source: International Congress 2016 – IPF treatment II Year: 2016 LATE-BREAKING ABSTRACT: Detrimental effects of medically indicated oral anticoagulation on survival in idiopathic pulmonary fibrosis (IPF) Source: International Congress 2015 – Latest developments in clinical studies in acute and chronic lung diseases Year: 2015 Serum surfactant protein D may predict the effect of pirfenidone in idiopathic pulmonary fibrosis Source: Annual Congress 2013 –Idiopathic pulmonary fibrosis and rarities Year: 2013 Intravenous pulse doses of high-dose corticosteroid and cyclophosphamide in acute exacerbation of idiopathic pulmonary fibrosis Source: International Congress 2015 – IPF: from bench to bedside Year: 2015 Pirfenidone treatment in idiopathic pulmonary fibrosis: An Italian case series Source: Annual Congress 2013 –Idiopathic pulmonary fibrosis: clinical view Year: 2013 Negative outcome of prednisone in possible idiopathic pulmonary fibrosis Source: International Congress 2016 – IPF clinical Year: 2016